Skip to main content
OpenTrials
Completed

NCT Number: NCT03211507

Idiopathic Pulmonary Fibrosis Job Exposures Study

A case-control study to investigate whether job exposures are an under-recognized cause of idiopathic pulmonary fibrosis (IPF) using an interview to collect information about previous jobs and a blood test to investigate genetic susceptibility.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Male

Study type

Observational

Primary location

Imperial Healthcare NHS Trust

London, United Kingdom

About this study

Idiopathic pulmonary fibrosis (IPF) is a scarring lung disease. It damages the air sacs that allow oxygen to be transferred into the blood and transported to vital organs. These changes make people with IPF cough and feel short of breath. It not known what causes the damage. People who get IPF are usually older than 40; it's a very serious illness that cannot be cured and gets worse over time. Statistics show that IPF is becoming more common in the UK but it's not known why. It can be difficult for doctors to tell if someone has IPF or another disease called asbestosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

For cases

Inclusion criteria

  • New diagnosis of IPF between February 2017 and October 2019

Exclusion criteria

  • Unable to give informed consent
  • Ever worked outside of the UK

For controls

Inclusion criteria

  • New outpatient department attendee between February 2017 and October 2019

Exclusion criteria

  • Unable to give informed consent
  • Ever worked outside of the UK (does not include work outside the UK by members of the armed forces or merchant navy)
  • Diagnosis of IPF

Treatment and study plan

Computer-assisted telephone interview

Other

Occupational history

Genetic analysis

Genetic

To include analysis of known susceptibility markers

Primary outcomes

  1. Association between asbestos exposure and IPF

    Time frame: 2 years

    estimated using logistic regression for any vs no asbestos exposure and adjusting for age and smoking status

Secondary outcomes

  1. Dose-response relationship between asbestos exposure and IPF

    Time frame: 2 years

    estimated using logistic regression for categories of cumulative exposure and adjusting for age and smoking status

  2. Gene-environment interaction (for MUC5B rs35705950 and asbestos exposure) odds ratio.

    Time frame: 2 years

    MUC5B rs35705950 and asbestos exposure odds ratio.

Sponsors and collaborators

Lead sponsor

Imperial College London

Other

Collaborators

  • Aberdeen Royal Infirmary
  • Glasgow Royal Infirmary
  • Guy's and St Thomas' NHS Foundation Trust
  • Heart of England NHS Foundation Trust
  • Imperial College Healthcare NHS Trust
  • Liverpool University Hospitals NHS Foundation Trust
  • Morriston Hospital
  • Newcastle-upon-Tyne Hospitals NHS Trust
  • Norfolk and Norwich University Hospitals NHS Foundation Trust
  • North Bristol NHS Trust
  • Nottingham University Hospitals NHS Trust
  • Papworth Hospital NHS Foundation Trust
  • Portsmouth Hospitals NHS Trust
  • Royal Devon and Exeter NHS Foundation Trust
  • Royal Infirmary of Edinburgh
  • Somerset NHS Foundation Trust
  • The Leeds Teaching Hospitals NHS Trust
  • University Hospital Birmingham NHS Foundation Trust
  • University Hospital Southampton NHS Foundation Trust
  • University Hospital of South Manchester
  • Wellcome Trust
  • Worcestershire Acute Hospitals NHS Trust

Registry information

Acronym: IPFJES

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Jul 7, 2017
Registry last updated
Dec 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.